drugset / Trial / NCT00245466
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
Timeline
- Start
- 2001-10
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 20 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 40 mg | Subcutaneous |